Real World Evidence Studies Presented in ISPOR 2022: A Descriptive Analysis of Research Posters


Vallish BN1, Dang A2
1MarksMan Healthcare Communications, Hyderabad, India, 2MarksMan Healthcare Communications, Hyderabad, AP, India

OBJECTIVES: To descriptively analyze all posters about real-world evidence (RWE) studies presented in ISPOR 2022

METHODS: We accessed the virtual platform of ISPOR 2022 and printed out the posters that were categorized under “Real world data and information systems (RWD & IS)”. Extracted data included first author affiliation, setting (academia/ industry), SDC/ STA details, nature and source of RWD, presence of information about study limitations and disclosures in the poster. We also compared the contents of the poster and the abstract.

RESULTS: A total of 1,453 posters were presented in ISPOR 2022, out of which 133 (9.15%) were tagged under RWD & IS. 86 (65.6%) were presented in-person. 106 unique first authors presented posters; 88 (67%) posters were from first authors with industry affiliation. Most frequent disease area was oncology (40/131, 30.5%); most frequent type of RWD source used was claims database (43/131, 32.8%). Most studies included patients from USA (76/131, 58%). Sample size varied from 40 patients to 531 million patients; 9 studies had >1 million participants. 20 studies had significant disparity between poster content and abstract content. Study limitations and disclosures were found in 40 and 48 studies only.

CONCLUSIONS: RWE studies presented in ISPOR 2022 gave a glimpse of ongoing RWE research

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)




No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now